Trial · NCT05875714
Apremilast for Erythema Multiforme
NCT05875714, Phase 2, Completed, Robert Micheletti
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Apremilast for Erythema Multiforme. Trials, record NCT05875714. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05875714
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Apremilast for Erythema Multiforme
- NCT number
- NCT05875714
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Robert Micheletti
- Conditions
- Erythema Multiforme
- Interventions
- Apremilast
- First posted
- 2023-05-25
- Last updated
- 2026-06-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Erythema Multiforme Flares on Medication | 24 weeks | Number of flares occurring in 24 weeks on apremilast compared to the preceding 24 weeks |
| Secondary | Pain on Medication | 24 weeks | Average pain severity of erythema multiforme at 24-week evaluation (units on a 0 to 10 scale; 10 = maximum pain) |
| Secondary | Number of Flares Weeks 24-36 | 36 weeks | Number of erythema multiforme flares occurring in the 12 weeks after completing the 24-week course of apremilast |
| Secondary | Average Pain Associated With Flares in Weeks 24-36 | 36 weeks | Average pain severity (units on a 0-10 scale; 10 = maximum pain) associated with erythema multiforme flares occurring in the 12 weeks after completing the 24-week course of apremilast |
| Secondary | Autoimmune Bullous Disease Quality of Life Score | 24-weeks | 17-item patient-reported tool developed to measure the significant impact of rare blistering skin conditions (Autoimmune Bullous Diseases or AIBDs) on a person's daily life, focusing on symptoms, physical function, social impact, and psychological well-being |
| Secondary | Investigator Global Assessment | 24 weeks | Investigator global assessment of disease severity (units on a 0-10 scale; 10 is max severity) |
| Secondary | Autoimmune Bullous Disease Quality of Life Score | Week 36 | |
| Secondary | Investigator Global Assessment--week 36 | Week 36 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05875714
GET https://conductscience.org/api/trials/v1/NCT05875714/registered